Sahajanand Medical Technologies IPO Details
IPO Overview
| Price Band | ₹327–₹344 |
|---|---|
| Lot Size | 43 shares |
| Min Investment | Min ₹14792 |
| GMP | ₹41 (11.92%) |
| Total Subscription | 0 times |
| Status | Upcoming |
Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 43 | 14792 |
| Retail (Max) | 13 | 559 | 192296 |
| S-HNI (Min) | 14 | 602 | 207088 |
| S-HNI (Max) | 67 | 2881 | 991064 |
| B-HNI (Min) | 68 | 2924 | 1005856 |
IPO Tentative Timetable
| IPO Open Date | Oct 15, 2026 |
|---|---|
| IPO Close Date | Oct 19, 2026 |
| Allotment Date | Oct 21, 2026 |
| Refund Initiation | Oct 22, 2026 |
| Listing Date | Oct 23, 2026 |
IPO Detail
| Face Value | ₹1 per share |
|---|---|
| Price Band | ₹327 to ₹344 |
| Lot Size | 43 Shares |
| Sale Type | OFS only |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Total Issue Size | 1,38,22,116 shares (agg. up to ₹475 Cr) |
| Offer for Sale | 1,38,22,116 shares of ₹1 (agg. up to ₹475 Cr) |
| Share Holding Pre Issue | 10,16,46,778 shares |
| Share Holding Post Issue | 10,16,46,778 shares |
Company Financials (In Crore)
| Period Ended | Assets | Total Income | Profit After Tax | E B I T D A | N E T Worth | Reserves And Surplus | Total Borrowing |
|---|---|---|---|---|---|---|---|
| 30 Jun 2026 | 1,309.00 | 354.33 | 15.09 | 48.58 | 631.72 | 706.86 | 320.63 |
| 31 Mar 2026 | 1,276.43 | 1,218.73 | 69.08 | 170.66 | 616.05 | 692.48 | 269.53 |
| 31 Mar 2025 | 1,094.90 | 1,035.96 | 25.15 | 128.02 | 545.23 | 580.71 | 224.96 |
| 31 Mar 2024 | 970.58 | 908.59 | -7.35 | 110.05 | 526.30 | 556.57 | 175.27 |
About Company
Founded in 2001 by Mr. Dhirajlal Kotadia, Sahajanand Medical Technologies Ltd. is a medical device company focused on Class III and Class C/D devices, primarily in the fields of vascular and structural heart intervention. The company was the first globally to receive CE certification for a drug-eluting stent (DES) with a biodegradable polymer—Infinnium.
The product portfolio spans three key categories:
- Vascular Intervention (VI): Includes coronary stents and balloons for minimally invasive blood vessel treatments.
- Structural Heart (SH): Covers advanced technologies such as Transcatheter Aortic Valve Implantation (TAVI) and Occluders.
- Other Products: Includes renal stents, peripheral Drug-Coated Balloons (DCBs), and selected trading products.
Sahajanand operates two R&D centers—one in India and one in Thailand—supported by a team of 102 professionals, including biomedical engineers and clinical research specialists. The company has built a robust intellectual property base, with 102 patents granted globally and 71 pending patent applications, along with five design registrations in India.
Key products such as Supraflex Cruz (DES), Hydra (TAVI), and Cocoon (Occluders) are backed by 72 clinical studies, and are widely accepted in over 76 countries across Europe, Asia, and other regions. The global distribution strategy includes direct operations in key European markets (Germany, Spain, France, UK), hybrid models in India (serving hospitals like Narayana Hrudayalaya Limited), and distributor-led entry in markets such as Italy.
International market adoption is reinforced by endorsements from key opinion leaders (KOLs), successful government tenders, and partnerships with major Group Purchasing Organizations (GPOs) in Europe.
The company follows a “House of Brand” strategy, developing and commercializing clinically differentiated products under recognized brand names like Supraflex Cruz, Hydra, and Cocoon.
As of March 31, 2025, Sahajanand Medical Technologies employed 1,458 full-time staff, 24 consultants, and 818 contract-based personnel across its operations.
Sahajanand Medical Technologies IPO Details — Frequently Asked Questions
What is Sahajanand Medical Technologies IPO?
What is the price band of Sahajanand Medical Technologies IPO?
What is the lot size and minimum investment for Sahajanand Medical Technologies IPO?
When will Sahajanand Medical Technologies IPO open and close for subscription?
What is the issue size of Sahajanand Medical Technologies IPO?
When is the Sahajanand Medical Technologies IPO listing date?
Is Sahajanand Medical Technologies a Mainline IPO or SME IPO?
How can I apply for Sahajanand Medical Technologies IPO?
Disclaimer
No financial information published within this application, including but not limited to information regarding securities or IPOs, should be considered as advice to buy or sell securities or to invest in IPOs, or as a guide to doing so in any way whatsoever. All content published in this application is provided solely for educational and informational purposes, and under no circumstances should it be used for making investment decisions. We are not a SEBI registered analyst.
Readers must consult a qualified financial advisor before making any actual investment decisions based on information published in this application. The information in this application is based on information available as of the date of publication, along with market perceptions, and may be subject to change without notice.